Excitatory amino acids, S-nitrosylation, and protein misfolding in neurodegenerative disease: Protection by memantine and nitromemantine at NMDA-gated channels

Micronutrients and Brain Health

Volumn , Issue , 2009, Pages 59-78

  Nakamura, Tomohiro ^a   Lipton, Stuart A ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897453675     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (161)

1. Lin, M. T., and Beal, M. F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases, Nature 443, 787, 2006.
2. Barnham, K. J., Masters, C. L., and Bush, A. I., Neurodegenerative diseases and oxidative stress, Nat Rev Drug Discov 3, 205, 2004.
3. Muchowski, P. J., Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones? Neuron 35, 9, 2002.
4. Emerit, J., Edeas, M., and Bricaire, F., Neurodegenerative diseases and oxidative stress, Biomed Pharmacother 58, 39, 2004.
5. Beal, M. F., Experimental models of Parkinson’s disease, Nat Rev Neurosci 2, 325, 2001.
6. Lipton, S. A., and Rosenberg, P. A., Excitatory amino acids as a final common pathway for neurologic disorders, N Engl J Med 330, 613, 1994.
7. Lipton, S. A., Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond, Nat Rev Drug Discov 5, 160, 2006.
8. Bredt, D. S. et al., Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase, Nature 351, 714, 1991.
9. Garthwaite, J., Charles, S. L., and Chess-Williams, R., Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain, Nature 336, 385, 1988.
10. Beckman, J. S. et al., Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide, Proc Natl Acad Sci U S A 87, 1620, 1990.
11. Lipton, S. A. et al., A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds, Nature 364, 626, 1993.
12. Bence, N. F., Sampat, R. M., and Kopito, R. R., Impairment of the ubiquitin-proteasome system by protein aggregation, Science 292, 1552, 2001.
13. Chaudhuri, T. K., and Paul, S., Protein-misfolding diseases and chaperone-based therapeutic approaches, FEBS J 273, 1331, 2006.
14. Ciechanover, A., and Brundin, P., The ubiquitin proteasome system in neurodegenerative diseases:Sometimes the chicken, sometimes the egg, Neuron 40, 427, 2003.
15. Muchowski, P. J., and Wacker, J. L., Modulation of neurodegeneration by molecular chaperones, Nat Rev Neurosci 6, 11, 2005.
16. Zhang, K., and Kaufman, R. J., The unfolded protein response: A stress signaling pathway critical for health and disease, Neurology 66, S102, 2006.
17. Chung, K. K. et al., S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function, Science 304, 1328, 2004.
18. Yao, D. et al., Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity, Proc Natl Acad Sci U S A 101, 10810, 2004.
19. Lipton, S. A. et al., Comment on “S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function” Science 308, 1870; author reply 1870, 2005.
20. Uehara, T. et al., S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration, Nature 441, 513, 2006.
21. Lipton, S. A., Pathologically activated therapeutics for neuroprotection, Nat Rev Neurosci 8, 803, 2007.
22. Cookson, M. R., The biochemistry of Parkinson’s disease, Annu Rev Biochem 74, 29, 2005.
23. Zhao, L. et al., Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1, a cochaperone of BiP, Nat Genet 37, 974, 2005.
24. McNaught, K. S. et al., Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease, Ann Neurol 56, 149, 2004.
25. Auluck, P. K. et al., Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease, Science 295, 865, 2002.
26. Arrasate, M. et al., Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature 431, 805, 2004.
27. Hardingham, G. E., Fukunaga, Y., and Bading, H., Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways, Nat Neurosci 5, 405, 2002.
28. 2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection, J Neurosci 25, 4279, 2005.
29. Papadia, S. et al., Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses, Nat Neurosci 11, 476, 2008.
30. Ankarcrona, M. et al., Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function, Neuron 15, 961, 1995.
31. Bonfoco, E. et al., Apoptosis and necrosis: Two distinct events induced, respectively, by mild and intense insults with N-methyl-d-aspartate or nitric oxide/superoxide in cortical cell cultures, Proc Natl Acad Sci U S A 92, 7162, 1995.
32. Budd, S. L. et al., Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons, Proc Natl Acad Sci U S A 97, 6161, 2000.
33. Nowak, L. et al., Magnesium gates glutamate-activated channels in mouse central neurones, Nature 307, 462, 1984.
34. 2+ of NMDA responses in spinal cord neurones, Nature 309, 261, 1984.
35. Dawson, V. L. et al., Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures, Proc Natl Acad Sci U S A 88, 6368, 1991.
36. Lafon-Cazal, M. et al., NMDA-dependent superoxide production and neurotoxicity, Nature 364, 535, 1993.
37. Olney, J. W., Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate, Science 164, 719, 1969.
38. Olney, J. W., Wozniak, D. F., and Farber, N. B., Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies, Arch Neurol 54, 1234, 1997.
39. Chen, H. S., and Lipton, S. A., The chemical biology of clinically tolerated NMDA receptor antagonists, J Neurochem 97, 1611, 2006.
40. Abu-Soud, H. M., and Stuehr, D. J., Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer, Proc Natl Acad Sci U S A 90, 10769, 1993.
41. Forstermann, U., Boissel, J. P., and Kleinert, H., Expressional control of the “constitutive” isoforms of nitric oxide synthase (NOS I and NOS III), FASEB J 12, 773, 1998.
42. Boucher, J. L., Moali, C., and Tenu, J. P., Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for l-arginine utilization, Cell Mol Life Sci 55, 1015, 1999.
43. Groves, J. T., and Wang, C. C., Nitric oxide synthase: Models and mechanisms, Curr Opin Chem Biol 4, 687, 2000.
44. Betarbet, R. et al., Chronic systemic pesticide exposure reproduces features of Parkinson’s disease, Nat Neurosci 3, 1301, 2000.
45. He, Y. et al., Role of nitric oxide in rotenone-induced nigro-striatal injury, J Neurochem 86, 1338, 2003.
46. Abou-Sleiman, P. M., Muqit, M. M., and Wood, N. W., Expanding insights of mitochondrial dysfunction in Parkinson’s disease, Nat Rev Neurosci 7, 207, 2006.
47. Castello, P. R. et al., Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions:Implications for oxygen sensing and hypoxic signaling in eukaryotes, Cell Metab 3, 277, 2006.
48. Isaacs, A. M. et al., Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium, J Biol Chem 281, 27916, 2006.
49. O’Dell, T. J. et al., Tests of the roles of two diffusible substances in long-term potentiation: Evidence for nitric oxide as a possible early retrograde messenger, Proc Natl Acad Sci U S A 88, 11285, 1991.
50. Bredt, D. S., and Snyder, S. H., Nitric oxide: A physiologic messenger molecule, Annu Rev Biochem 63, 175, 1994.
51. Schuman, E. M., and Madison, D. V., Locally distributed synaptic potentiation in the hippocampus, Science 263, 532, 1994.
52. Stamler, J. S. et al., S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds, Proc Natl Acad Sci U S A 89, 444, 1992.
53. Lei, S. Z. et al., Effect of nitric oxide production on the redox modulatory site of the NMDA receptorchannel complex, Neuron 8, 1087, 1992.
54. Kandel, E. R., and O’Dell, T. J., Are adult learning mechanisms also used for development? Science 258, 243, 1992.
55. Stamler, J. S. et al., (S)NO signals: Translocation, regulation, and a consensus motif, Neuron 18, 691, 1997.
56. Hess, D. T. et al., Protein S-nitrosylation: Purview and parameters, Nat Rev Mol Cell Biol 6, 150, 2005.
57. Melino, G. et al., S-nitrosylation regulates apoptosis, Nature 388, 432, 1997.
58. Tenneti, L., D’Emilia, D. M., and Lipton, S. A., Suppression of neuronal apoptosis by S-nitrosylation of caspases, Neurosci Lett 236, 139, 1997.
59. Dimmeler, S. et al., Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases, J Exp Med 185, 601, 1997.
60. Mannick, J. B. et al., Fas-induced caspase denitrosylation, Science 284, 651, 1999.
61. Kim, W. K. et al., Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO, Neuron 24, 461, 1999.
62. Choi, Y. B. et al., Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation, Nat Neurosci 3, 15, 2000.
63. Gu, Z. et al., S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death, Science 297, 1186, 2002.
64. Hara, M. R. et al., S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding, Nat Cell Biol 7, 665, 2005.
65. Jaffrey, S. R. et al., Protein S-nitrosylation: A physiological signal for neuronal nitric oxide, Nat Cell Biol 3, 193, 2001.
66. Haendeler, J. et al., Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69, Nat Cell Biol 4, 743, 2002.
67. Sliskovic, I., Raturi, A., and Mutus, B., Characterization of the S-denitrosation activity of protein disulfide isomerase, J Biol Chem 280, 8733, 2005.
68. Stamler, J. S., Singel, D. J., and Loscalzo, J., Biochemistry of nitric oxide and its redox-activated forms, Science 258, 1898, 1992.
69. Stamler, J. S., Redox signaling: Nitrosylation and related target interactions of nitric oxide, Cell 78, 931, 1994.
70. Stamler, J. S., Lamas, S., and Fang, F. C., Nitrosylation. The prototypic redox-based signaling mechanism, Cell 106, 675, 2001.
71. Lipton, S. A. et al., Cysteine regulation of protein function - As exemplified by NMDA-receptor modulation, Trends Neurosci 25, 474, 2002.
72. Stamler, J. S., and Hausladen, A., Oxidative modifications in nitrosative stress, Nat Struct Biol 5, 247, 1998.
73. Houk, K. N. et al., Nitroxyl disulfides, novel intermediates in transnitrosation reactions, J Am Chem Soc 125, 6972, 2003.
74. Huang, Z. et al., Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase, Science 265, 1883, 1994.
75. Iadecola, C. et al., Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene, J Neurosci 17, 9157, 1997.
76. Hantraye, P. et al., Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons, Nat Med 2, 1017, 1996.
77. Przedborski, S. et al., Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, Proc Natl Acad Sci U S A 93, 4565, 1996.
78. Liberatore, G. T. et al., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease, Nat Med 5, 1403, 1999.
79. Chabrier, P. E., Demerle-Pallardy, C., and Auguet, M., Nitric oxide synthases: Targets for therapeutic strategies in neurological diseases, Cell Mol Life Sci 55, 1029, 1999.
80. Kitada, T. et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature 392, 605, 1998.
81. Valente, E. M. et al., Hereditary early-onset Parkinson’s disease caused by mutations in PINK1, Science 304, 1158, 2004.
82. Polymeropoulos, M. H. et al., Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease, Science 276, 2045, 1997.
83. Bonifati, V. et al., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science 299, 256, 2003.
84. Leroy, E. et al., The ubiquitin pathway in Parkinson’s disease, Nature 395, 451, 1998.
85. Paisan-Ruiz, C. et al., Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease, Neuron 44, 595, 2004.
86. Zimprich, A. et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron 44, 601, 2004.
87. Ramirez, A. et al., Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase, Nat Genet 38, 1184, 2006.
88. Ross, C. A., and Pickart, C. M., The ubiquitin-proteasome pathway in Parkinson’s disease and other neurodegenerative diseases, Trends Cell Biol 14, 703, 2004.
89. Shimura, H. et al., Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nat Genet 25, 302, 2000.
90. Marin, I., and Ferrus, A., Comparative genomics of the RBR family, including the Parkinson’s diseaserelated gene parkin and the genes of the Ariadne subfamily, Mol Biol Evol 19, 2039, 2002.
91. Farrer, M. et al., Lewy bodies and parkinsonism in families with parkin mutations, Ann Neurol 50, 293, 2001.
92. Sriram, S. R. et al., Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin, Hum Mol Genet 14, 2571, 2005.
93. Hampe, C. et al., Biochemical analysis of Parkinson’s disease-causing variants of parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity, Hum Mol Genet 15, 2059, 2006.
94. Matsuda, N. et al., Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro, J Biol Chem 281, 3204, 2006.
95. Lim, K. L. et al., Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1:Implications for Lewy body formation, J Neurosci 25, 2002, 2005.
96. Lim, K. L., Dawson, V. L., and Dawson, T. M., Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson’s and other conformational diseases? Neurobiol Aging 27, 524, 2006.
97. Shimura, H. et al., Ubiquitination of a new form of alpha-synuclein by parkin from human brain:Implications for Parkinson’s disease, Science 293, 263, 2001.
98. Chung, K. K. et al., Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease, Nat Med 7, 1144, 2001.
99. Imai, Y. et al., An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin, Cell 105, 891, 2001.
100. Zhang, Y. et al., Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1, Proc Natl Acad Sci U S A 97, 13354, 2000.
101. Staropoli, J. F. et al., Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity, Neuron 37, 735, 2003.
102. Corti, O. et al., The p38 subunit of the aminoacyl-tRNA synthetase complex is a parkin substrate: Linking protein biosynthesis and neurodegeneration, Hum Mol Genet 12, 1427, 2003.
103. Huynh, D. P. et al., The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI, Hum Mol Genet 12, 2587, 2003.
104. Ren, Y., Zhao, J., and Feng, J., Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation, J Neurosci 23, 3316, 2003.
105. Yamamoto, A. et al., Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity, J Biol Chem 280, 3390, 2005.
106. Imai, Y. et al., CHIP is associated with parkin, a gene responsible for familial Parkinson’s disease, and enhances its ubiquitin ligase activity, Mol Cell 10, 55, 2002.
107. Kalia, S. K. et al., BAG5 inhibits parkin and enhances dopaminergic neuron degeneration, Neuron 44, 931, 2004.
108. Fallon, L. et al., A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling, Nat Cell Biol 8, 834, 2006.
109. Moore, D. J. et al., Parkin mediates the degradation-independent ubiquitination of Hsp70, J Neurochem 105, 1806, 2008.
110. Liu, Y. et al., The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility, Cell 111, 209, 2002.
111. Nishikawa, K. et al., Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants, Biochem Biophys Res Commun 304, 176, 2003.
112. Choi, J. et al., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases, J Biol Chem 279, 13256, 2004.
113. Chung, K. K., Dawson, T. M., and Dawson, V. L., Nitric oxide, S-nitrosylation and neurodegeneration, Cell Mol Biol (Noisy-le-grand) 51, 247, 2005.
114. Gu, Z. et al., Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson’s disease, Cell Death Differ 12, 1202, 2005.
115. Wang, C. et al., Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function, Hum Mol Genet 14, 3885, 2005.
116. Wong, E. S. et al., Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations, J Biol Chem, 282, 12310, 2007.
117. LaVoie, M. J. et al., The effects of oxidative stress on parkin and other E3 ligases, J Neurochem 103, 2354, 2007.
118. LaVoie, M. J. et al., Dopamine covalently modifies and functionally inactivates parkin, Nat Med 11, 1214, 2005.
119. LaVoie, M. J., and Hastings, T. G., Peroxynitrite- and nitrite-induced oxidation of dopamine: Implications for nitric oxide in dopaminergic cell loss, J Neurochem 73, 2546, 1999.
120. Andrews, D. W., and Johnson, A. E., The translocon: More than a hole in the ER membrane? Trends Biochem Sci 21, 365, 1996.
121. Sidrauski, C., Chapman, R., and Walter, P., The unfolded protein response: An intracellular signalling pathway with many surprising features, Trends Cell Biol 8, 245, 1998.
122. Szegezdi, E. et al., Mediators of endoplasmic reticulum stress-induced apoptosis, EMBO Rep 7, 880, 2006.
123. Ellgaard, L., Molinari, M., and Helenius, A., Setting the standards: Quality control in the secretory pathway, Science 286, 1882, 1999.
124. Kaufman, R. J., Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls, Genes Dev 13, 1211, 1999.
125. Mori, K., Tripartite management of unfolded proteins in the endoplasmic reticulum, Cell 101, 451, 2000.
126. Patil, C., and Walter, P., Intracellular signaling from the endoplasmic reticulum to the nucleus: The unfolded protein response in yeast and mammals, Curr Opin Cell Biol 13, 349, 2001.
127. Yoshida, H. et al., XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor, Cell 107, 881, 2001.
128. Lyles, M. M., and Gilbert, H. F., Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: Dependence of the rate on the composition of the redox buffer, Biochemistry 30, 613, 1991.
129. Edman, J. C. et al., Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin, Nature 317, 267, 1985.
130. Vuori, K. et al., Site-directed mutagenesis of human protein disulphide isomerase: Effect on the assembly, activity and endoplasmic reticulum retention of human prolyl 4-hydroxylase in Spodoptera frugiperda insect cells, EMBO J 11, 4213, 1992.
131. Ellgaard, L., and Ruddock, L. W., The human protein disulphide isomerase family: Substrate interactions and functional properties, EMBO Rep 6, 28, 2005.
132. Gruber, C. W. et al., Protein disulfide isomerase: The structure of oxidative folding, Trends Biochem Sci 31, 455, 2006.
133. Tian, G. et al., The crystal structure of yeast protein disulfide isomerase suggests cooperativity between its active sites, Cell 124, 61, 2006.
134. Conn, K. J. et al., Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson’s disease and Lewy body pathology, Brain Res 1022, 164, 2004.
135. Hetz, C. et al., The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity, J Neurosci 25, 2793, 2005.
136. Hu, B. R. et al., Protein aggregation after transient cerebral ischemia, J Neurosci 20, 3191, 2000.
137. Rao, R. V., and Bredesen, D. E., Misfolded proteins, endoplasmic reticulum stress and neurodegeneration, Curr Opin Cell Biol 16, 653, 2004.
138. Atkin, J. D. et al., Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1, J Biol Chem 281, 30152, 2006.
139. Tanaka, S., Uehara, T., and Nomura, Y., Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death, J Biol Chem 275, 10388, 2000.
140. Ko, H. S., Uehara, T., and Nomura, Y., Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death, J Biol Chem 277, 35386, 2002.
141. Gotoh, T. et al., Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP, J Biol Chem 277, 12343, 2002.
142. Oyadomari, S. et al., Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway, Proc Natl Acad Sci U S A 98, 10845, 2001.
143. Forrester, M. T., Benhar, M., and Stamler, J. S., Nitrosative stress in the ER: A new role for S-nitrosylation in neurodegenerative diseases, ACS Chem Biol 1, 355, 2006.
144. Xu, L. et al., Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation, Science 279, 234, 1998.
145. Tao, L. et al., Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis, Circulation 114, 1395, 2006.
146. Aracena-Parks, P. et al., Identification of cysteines involved in S-nitrosylation, S-glutathionylation, and oxidation to disulfides in ryanodine receptor type 1, J Biol Chem 281, 40354, 2006.
147. Martinez-Ruiz, A. et al., S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities, Proc Natl Acad Sci U S A 102, 8525, 2005.
148. Kakimura, J. et al., Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins, FASEB J 16, 601, 2002.
149. Dou, F. et al., Chaperones increase association of tau protein with microtubules, Proc Natl Acad Sci U S A 100, 721, 2003.
150. Gray, D. A., Tsirigotis, M., and Woulfe, J., Ubiquitin, proteasomes, and the aging brain, Sci Aging Knowledge Environ 2003, RE6, 2003.
151. Paz Gavilan, M. et al., Cellular environment facilitates protein accumulation in aged rat hippocampus, Neurobiol Aging 27, 973, 2006.
152. Ditzler, K., Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial, Arzneimittelforschung 41, 773, 1991.
153. Fleischhacker, W. W., Buchgeher, A., and Schubert, H., Memantine in the treatment of senile dementia of the Alzheimer type, Prog Neuropsychopharmacol Biol Psychiatry 10, 87, 1986.
154. Parsons, C. G., Danysz, W., and Quack, G., Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - A review of preclinical data, Neuropharmacology 38, 735, 1999.
155. Chen, H. S. et al., Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine:Therapeutic advantage against NMDA receptor-mediated neurotoxicity, J Neurosci 12, 4427, 1992.
156. Chen, H. S. et al., Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation, Neuroscience 86, 1121, 1998.
157. Lipton, S. A., Memantine prevents HIV coat protein-induced neuronal injury in vitro, Neurology 42, 1403, 1992.
158. Osborne, N. N., Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia, Vis Neurosci 16, 45, 1999.
159. Lipton, S. A., and Wang, Y. F., NO-related species can protect from focal cerebral ischemia/reperfusion, in Pharmacology of Cerebral Ischemia, Krieglstein, J., and Oberpichler-Schwenk, H., Eds., Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 1996, pp. 183.
160. Zurakowski, D. et al., Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors, Vision Res 38, 1489, 1998.
161. Takahashi, H. et al., Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif, Neuron 53, 53, 2007.